NCT06276283View on ClinicalTrials.gov

DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 15, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

February 28, 2026

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

DZD9008 plus Bevacizumab

DZD9008, 200 mg or 300 mg, once daily plus Bevacizumab 15 mg/kg, once every 3 weeks

Trial Locations (1)

200030

RECRUITING

Shanghai Chest Hospital, Shanghai

Sponsors
All Listed Sponsors
lead

Dizal Pharmaceuticals

INDUSTRY